Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 30, 2024
Daily News
September 30, 2024
- Astellas Touts Confirmed Safety and Antitumor Effects of Protein Degrader
September 30, 2024
- Sawai Ordered to Pay 3 Billion Yen in Damages in Teribone Suit, Set to Appeal
September 30, 2024
- Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies
September 30, 2024
- 8 South Korean Biotechs Now Housed at Shonan iPark
September 30, 2024
- Shionogi Files Sage’s Depression Drug in Japan
September 30, 2024
- Japan Generic Use Rate Reaches 83.5% in April-June: JGA
September 30, 2024
- 6 Tips for Motivating and Engaging Current Employees
September 30, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…